The potential of BORIS detected in the leukocytes of breast cancer patients as an early marker of tumorigenesis
The potential of BORIS detected in the leukocytes of breast cancer patients as an early marker of tumorigenesis
复制标题
DOI：
10.1158/1078-0432.ccr-05-2731
复制
发表时间：
2006-10-15
影响因子：
11.5
通讯作者：
Klenova, Elena
中科院分区：
文献类型：
--
作者：
Darcy, Vivien;Abdullaev, Ziedulla K.;Klenova, Elena
目的：印迹位点调节因子兄弟（Brother of the regulator of imprinted sites，BORIS）是肿瘤睾丸抗原基因家族的新成员。这些基因通常只在精母细胞中表达，但在不同的恶性肿瘤（包括乳腺癌）中异常激活。本研究的目的是探讨乳腺癌患者的白细胞中BORIS的表达和BORIS水平和临床/病理变量之间的相关性。实验设计：白细胞从87例乳腺癌患者和52名未诊断为癌症的供体的全血中获得。通过免疫组化染色检测白细胞中的BORIS蛋白;测定每个样品的免疫反应性评分（IRS）。此外，BORIS的表达进行了评估，Western印迹分析和实时逆转录-PCR.Results：我们描述了显着高水平的BORIS（IRS = 4.25 +/- 0.034）的白细胞亚群，中性粒细胞多形核粒细胞，在88.5%的乳腺癌患者。这些患者中BORIS的IRS增加与肿瘤大小的增加相关。与对照组相比，19.2%的样本BORIS阳性，只有非常低的水平BORIS（IRS = 0.25 +/- 0.009）。结论：我们在这里报告的新发现BORIS表达在乳腺癌患者的多形核粒细胞。这种与肿瘤相关的发生是在有损伤和免疫和炎症疾病的供体中未观察到的现象。BORIS在各种类型乳腺肿瘤患者中的高比例检测表明BORIS可以成为乳腺癌的有价值的早期血液标志物。我们的结论是，BORIS代表了一类新的癌症生物标志物，不同于目前在医疗实践中使用的那些。
Purpose: Brother of the regulator of imprinted sites (BORIS) is a novel member of the cancer testis antigen gene family. These genes are normally expressed only in spermatocytes but abnormally activated in different malignancies, including breast cancer. The aim of this study was to investigate the expression of BORIS in the leukocytes of breast cancer patients and the correlation between BORIS levels and clinical /pathologic variables.Experimental Design: Leukocytes were obtained from whole blood of 87 breast cancer patients and 52 donors not diagnosed with cancer. BORIS protein was detected in leukocytes by immunohistochemical staining; the immunoreactivity score (IRS) of each sample was determined. Additionally, BORIS expression was assessed by Western blot analysis and real-time reverse transcription-PCR.Results: We describe significantly high levels of BORIS (IRS = 4.25 +/- 0.034) in a subpopulation of leukocytes, the neutrophil polymorphonuclear granulocytes, in 88.5% of breast cancer patients. Increased IRS for BORIS in these patients correlated with increased tumor size. In comparison, 19.2% samples from the control group were BORIS positive with only very low levels of BORIS (IRS = 0.25 +/- 0.009).Conclusion: We report here the novel finding of BORIS expression in polymorphonuclear granulocytes of breast cancer patients. This tumor-related occurrence is a phenomenon not observed in donors with injuries and immune and inflammatory diseases. Detection of BORIS in a high proportion of patients with various types of breast tumors indicates that BORIS can be a valuable early blood marker of breast cancer. We conclude that BORIS represents a new class of cancer biomarkers different from those currently used in medical practice.